ACADIA PHARMACEUTICALS INC. AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • December 21st, 2000 • Acadia Pharmaceuticals Inc
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSEER SET FORTH IN SECTION 4 OF THIS WARRANTAcadia Pharmaceuticals Inc • December 21st, 2000 • Delaware
6,250,000 Shares ACADIA PHARMACEUTICALS INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 18th, 2019 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
JOINT FILING AGREEMENTJoint Filing Agreement • September 3rd, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G, dated May 26, 2004, (the "Schedule 13G"), with respect to the Common Stock, $0.0001 par value per share, of Acadia Pharmaceuticals Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
RECITALSIndemnity Agreement • December 21st, 2000 • Acadia Pharmaceuticals Inc • Delaware
CORPORATEPLAN FOR RETIREMENT 100-SM- THE PROFIT SHARING/401(K) PLAN FIDELITY BASIC PLAN DOCUMENT NO. 10Acadia Pharmaceuticals Inc • December 21st, 2000 • Massachusetts
LOGO] AMERICAN INDUSTRIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE-NET (DO NOT USE THIS FORM FOR MULTI- TENANT BUILDINGS) 1. BASIC PROVISIONS ("BASIC PROVISIONS") 1.1 PARTIES: This Lease ("LEASE"), dated for reference...Acadia Pharmaceuticals Inc • December 21st, 2000
ACADIA Pharmaceuticals Inc. [ ] Shares Common Stock UNDERWRITING AGREEMENT dated [ ], 2004Underwriting Agreement • May 19th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 7th, 2016 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of January 6, 2016, by and between ACADIA Pharmaceuticals Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 7th, 2008 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 4, 2008, is by and between ACADIA PHARMACEUTICALS INC. (the “Company”) and KINGSBRIDGE CAPITAL LIMITED (the “Investor”).
AMONGAnd License Agreement • December 21st, 2000 • Acadia Pharmaceuticals Inc • California
ACADIA PHARMACEUTICALS INC. Common Stock (par value $0.0001 per share) At-The- Market Issuance Sales AgreementSales Agreement • March 30th, 2012 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
ACADIA Pharmaceuticals Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 18th, 2012 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of December 12, 2012, is made by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”).
ACADIA Pharmaceuticals Inc. 5,750,000 Shares Common Stock UNDERWRITING AGREEMENT dated April 4, 2007 Banc of America Securities LLC Lehman Brothers Inc. Deutsche Bank Securities Inc. Piper Jaffray & Co. JMP Securities LLC Rodman & Renshaw, LLCUnderwriting Agreement • April 5th, 2007 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
The lock-up restriction described in the previous paragraph shall not apply to: (1) bona fide gifts to, or transfers to a trust for, the direct or indirect benefit of the undersigned or the immediate family of the undersigned, (2) any shares of Common Stock sold pursuant to any 10b5-1 plan existing on or prior to the date hereof, and (3) the entering into a 10b5-1 plan during the Lock-Up Period so long as no shares of Common Stock are sold pursuant to such 10b5-1 plan during the Lock-Up Period; provided that in any transaction described in clause (1) above, (x) prior to such donation, transfer or distribution, such donee, transferee, or distributee shall execute and deliver to the Representatives a duplicate form of this lock-up agreement and (y) the undersigned shall not be required to, and shall not voluntarily, file a report under Section 16(a) of the Exchange Act. For purposes of this lock-up agreement, “immediate family” shall mean any relationship by blood, marriage or adoption,
COMMON STOCK PURCHASE AGREEMENT by and between KINGSBRIDGE CAPITAL LIMITED and ACADIA PHARMACEUTICALS INC. dated as of August 4, 2008Common Stock Purchase Agreement • August 7th, 2008 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
This COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of the 4th day of August, 2008, by and between Kingsbridge Capital Limited, an entity organized and existing under the laws of the British Virgin Islands, whose business address is P.O. Box 1075, Elizabeth House, 9 Castle Street, St. Helier, Jersey, Channel Islands (the “Investor”), and ACADIA Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”).
ACADIA PHARMACEUTICALS INC. INDEMNITY AGREEMENTIndemnity Agreement • February 27th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) is made and entered into as of , 2004 by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and (“Agent”).
LEASE AND LEASE AGREEMENT Between Boston Properties Limited Partnership The Landlord And ACADIA PHARMACEUTICALS INC. The Tenant For Leased Premises In 502 Carnegie Center Princeton, New Jersey May 15, 2018Lease and Lease Agreement • February 28th, 2023 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
LEASE AND LEASE AGREEMENT, dated as of May 15, 2018, between Boston Properties Limited Partnership, a Delaware limited partnership with offices c/o Boston Properties at 101 Carnegie Center, Suite 104, Princeton, New Jersey 08540 (the “Landlord”), and ACADIA Pharmaceuticals Inc., a Delaware corporation, with its principal office at 3611 Valley Centre Drive, Suite 300, San Diego, California 92130 (the “Tenant”).
SUBLEASE AGREEMENTOffice Lease • February 26th, 2015 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
This Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between KILROY REALTY, L.P., a Delaware limited partnership (“Landlord”), and TRION WORLDS, INC., a Delaware corporation (“Tenant”).
EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "AGREEMENT"), made this 31st day of January 1997, is entered into by RECEPTOR TECHNOLOGIES, INC., a Delaware corporation with its principal place of business at 276 East Allen Street, Winooski,...Employment Agreement • December 21st, 2000 • Acadia Pharmaceuticals Inc • Delaware
ONE PASEO OFFICE LEASEOffice Lease • February 27th, 2019 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
This Office Lease (this "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and ACADIA PHARMACEUTICALS INC., a Delaware corporation ("Tenant").
FORM OF WARRANTAcadia Pharmaceuticals Inc • December 21st, 2012 • Pharmaceutical preparations • New York
THIS CERTIFIES THAT, for value received, , with its principal office at , or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from ACADIA Pharmaceuticals Inc., a Delaware corporation, with its principal office at 3911 Sorrento Valley Blvd., San Diego, CA 92121 (the “Company”) up to shares of the Common Stock of the Company (the “Common Stock”), subject to adjustment as provided herein. This Warrant is one of a series of Warrants being issued pursuant to the terms of the Securities Purchase Agreement, dated December 12, 2012, by and among the Company and the original Holder of this Warrant and the other parties named therein (the “Purchase Agreement”). Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to such terms in the Purchase Agreement.
DEVELOPMENT AGREEMENTDevelopment Agreement • May 25th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of May 3, 2004 (the “Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and THE STANLEY MEDICAL RESEARCH INSTITUTE, a nonprofit organization (“SMRI”), having offices at 5430 Grosvenor Lane, Suite 200, Bethesda, Maryland 20814.
Master Manufacturing Services Agreement August 3, 2015Product Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each Party), and intending to be legally bound the Parties agree as follows:
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 5th, 2014 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into effective as of July 15, 2014 by and between ACADIA Pharmaceuticals Inc., a Delaware Corporation (the “Company”), and Stephen R. Davis (“EXECUTIVE”). The Company and EXECUTIVE are hereinafter collectively referred to as the “Parties”, and individually referred to each as a “Party”.
RECITALSDiscovery Collaboration Agreement • December 21st, 2000 • Acadia Pharmaceuticals Inc • Massachusetts
EXHIBIT 10.11 STOCK PLEDGE AGREEMENT THIS STOCK PLEDGE AGREEMENT ("PLEDGE AGREEMENT") is made by ULI HACKSELL, an individual with a residence at 10819 Bonjon Lane, San Diego, California 92131 ("PLEDGOR"), in favor of ACADIA PHARMACEUTICALS INC., a...Stock Pledge Agreement • February 5th, 2001 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Among ACADIA PHARMACEUTICALS INC., ALLERGAN, INC. and ALLERGAN SALES, LLCAnd License Agreement • May 25th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of March 27, 2003 (the “Effective Date”) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and Allergan, Inc., a Delaware corporation, and Allergan Sales, LLC, a Delaware limited liability company (collectively “Allergan”), both having offices at 2525 Dupont Drive, Irvine, California 92612.
First Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • August 4th, 2016 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to Product Agreement (the “Amendment”), dated April 25, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
PRODUCT AGREEMENTProduct Agreement • February 28th, 2024 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
Pursuant to the Master Manufacturing Services Agreement dated August 3, 2015 between Patheon Pharmaceuticals Inc., and Acadia Pharmaceuticals Inc., as amended January 1, 2022 (collectively the “Master Agreement”), this Product Agreement (this “Product Agreement” or “PA”) is effective as of May 1, 2022 (the “Effective Date”), and is entered into by Acadia Pharmaceuticals Inc., a Delaware corporation having its principal place of business at 12830 El Camino Real, Suite 400, San Diego, California 92130 ( “Acadia” or “Client”), and Patheon Pharmaceuticals Inc., having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237( “Patheon”) on behalf of itself and its Affiliates, as defined in Section 1.3 of the Master Agreement) within the Thermo Fisher Scientific Inc. Pharma Services Group. Patheon and Acadia may be collectively referred to as the parties and individually as a party.
First Amendment to Product Agreement between Patheon Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc.Product Agreement • May 6th, 2021 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment to Product Agreement (the “Amendment”), dated April 25, 2016 (the “Amendment Date”), is made by and between Patheon Pharmaceuticals Inc. (“Patheon”) and ACADIA Pharmaceuticals Inc. (“ACADIA”).
ACADIA PHARMACEUTICALS INC. WARRANT TO PURCHASE COMMON STOCKAcadia Pharmaceuticals Inc • May 10th, 2005 • Pharmaceutical preparations • New York
THIS CERTIFIES THAT, for value received, , with its principal office at , or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from ACADIA Pharmaceuticals Inc., a Delaware corporation, with its principal office at 3911 Sorrento Valley Blvd., San Diego, CA 92121 (the “Company”) up to shares of the Common Stock of the Company (the “Common Stock”), subject to adjustment as provided herein. This Warrant is one of a series of Warrants being issued pursuant to the terms of the Securities Purchase Agreement, dated April 15, 2005, by and among the Company and the original Holder of this Warrant and the other parties named therein (the “Purchase Agreement”). Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to such terms in the Purchase Agreement.
COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 27th, 2018 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Commercial Supply Agreement is made as of this 22nd day of February, 2018 (the “Effective Date”), by and between ACADIA Pharmaceuticals Inc., a Delaware corporation, with a place of business at 3611 Valley Centre Drive, Suite 300, San Diego, California 92130 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
ContractAcadia Pharmaceuticals Inc • August 3rd, 2023 • Pharmaceutical preparations • New York
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • September 24th, 2010 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to the Common Stock Purchase Agreement, dated as of September 21, 2010 (this “Amendment”), to the Common Stock Purchase Agreement dated as of August 4, 2008 (the “Purchase Agreement”) is entered into by and between ACADIA Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and Kingsbridge Capital Limited, an entity organized and existing under the laws of the British Virgin Islands (the “Investor”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 5th, 2009 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of May 1, 2009 (the “Effective Date”) between ACADIA PHARMACEUTICALS INC., a company organized under the laws of the State of Delaware, United States (“ACADIA”), and having a principal place of business at 3911 Sorrento Valley Boulevard, San Diego, California, United States, and BIOVAIL LABORATORIES INTERNATIONAL SRL, a Barbados society with restricted liability (“BLS”), having its registered office at Welches, Christ Church, Barbados WI, BB17154.
